FDA Accepts For Review Merck & Co., Inc. (MRK)’s Biologics License Application For V503, Investigational 9-valent Human Papillomavirus Vaccine
2/20/2014 8:52:20 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration.
Help employers find you! Check out all the jobs and post your resume.
comments powered by